SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

VDRM RSS Feed
Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Clonefan, whatarush12, knowmystuff
Search This Board: 
Last Post: 8/20/2017 4:03:15 PM - Followers: 494 - Board type: Free - Posts Today: 80


VDRM

ViaDerma, Inc.

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
     

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744

Email:  info@viadermalicensing.com

LINKS TO:
 

                             Most Recent News    

Most Recent Filings and Disclosures

 

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Verified by Transfer Agent

Authorized Shares: 400,000,000 a/o June 30, 2017

Outstanding Shares: 380,214,603 a/o June 30, 2017

(Restricted 65,575,478 - Unrestriced 314,239,125) a/o June 30, 2017

Held at DTC - N/A

Float: 222,337,825 a/o Jan 25, 2017

Par Value    0.001


-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

1) EXTREMELY OVERSOLD and unknown 
2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 
4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION!
6) WON AWARD FOR THEIR DRUG
7) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
8) THEY HAVE A PATENT which big boys have to be eyeing.

VDRM IS A HIDDEN GOLDMINE

THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HUGE:
 

VDRM ENTERS MMJ PLAYING FIELD

LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.


 



"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

 
INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
 PATENTS TRADEMARKS
NAME NUMBER NOTES NAME NUMBER STATUS
2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name Owner Registered Otiko's Role
BIOGENX
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
TBD
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
TBD CA
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.
 

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

May 03, 2017

OTC Disclosure & News Service

- ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

 

The Company plans on vigorously defending a lawsuit filed by Steven Keough in South Dakota that it believes was filed to stall the product launch of the Company's FDA Registered Viabecline. The Company is also evaluating its own claims against Keough and intends on filing its own claims against Keough.

LOS ANGELES, CA--(Marketwired - May 03, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company's legal counsel, Austin Legal Group, will be addressing the complaint filed by Steven J. Keogh in South Dakota Federal Court. The complaint alleges issues dating back to 2011 which the Company believes have been addressed, and the Company is evaluating potential counter claims against the plaintiff. The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.

The Company's President, Dr. Christopher Otiko, stated, "The Company's legal counsel will vigorously defend this civil legal action to protect our shareholders and the Company's patent pending product line. The Company is moving ahead with its aggressive growth plans and plans to complete its initial production of Viabecline topical antibiotic by the end of Q2."

 

RECENT NEWS
08/18/17 http://www.otcmarkets.com/stock/VDRM/news/ViaDerma--Inc--Set-to-Begin-Sales-of-its-FDA-Registered-Topical-Antibiotic-in-September-with-Initial-Orders-from-Japan?id=167639&b=y

06/27/2017- Viaderma, Inc Receives National Drug Code (NDC) from the FDA for Prolayed, It's New OTC Drug for Premature Ejaculation For Men

06/12/17 - ViaDerma, Inc. Commences First Manufacturing Run And Will Meet the 2nd Quarter Product Distribution Milestone  

05/15/17 - Viaderma, Inc. Recevies Positive Results On Phase I Testing In Canada With Its Proprietary THC delivery and moves to Phase II Trials and Development Of New Products With Its MMJ Technologies 


05/03/17 - ViaDerma, Inc. Will Vigorously Defend The Company's Patents, Product Line, and its Shareholders from current complaint against the company 

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes


02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results


01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017


12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

 
VDRM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#26490  Sticky Note VDRM PE Ratios $1.00 to $5.00 Targets TradeTime 08/20/17 10:19:27 AM
#26096  Sticky Note HUGE NEWS! VDRM ViaDerma, Inc. Set to Begin Momostocktrades 08/18/17 08:23:12 AM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#26557   A lot more room to run, RSI 43, yankees18 08/20/17 04:03:15 PM
#26556   You must have missed my previous chart... dragon52 08/20/17 03:59:29 PM
#26555   Anything can happen, why did OWC* run to jlcali621 08/20/17 03:54:22 PM
#26554   Done....got my first tweet out a minute ago. BigBlackDog 08/20/17 03:48:14 PM
#26553   Okay team. It's time to take to Twitter. knowmystuff 08/20/17 03:27:57 PM
#26552   I heard of someone offered a price above hans1111 08/20/17 03:13:00 PM
#26551   Revenue is a game changer. 1$ does sound Leadbelly11 08/20/17 02:48:21 PM
#26550   It all depends on many things but folks knowmystuff 08/20/17 02:33:16 PM
#26549   what do you think this could realistically go chico2663 08/20/17 02:30:57 PM
#26548   Well I suspect there will be additional countries Leadbelly11 08/20/17 02:20:03 PM
#26547   i tried to buy thursday at more than chico2663 08/20/17 02:19:40 PM
#26546   i tried to buy thursday at more than chico2663 08/20/17 02:19:40 PM
#26545   Not sure. I don't see it running Cryptocol 08/20/17 02:17:57 PM
#26544   Belzoni 08/20/17 02:15:19 PM
#26543   I'll be first in line to buy tomorrow. Belzoni 08/20/17 02:15:18 PM
#26542   will they need to dilute if this runs chico2663 08/20/17 02:14:52 PM
#26541   Well lets change some zip codes then! Cryptocol 08/20/17 02:01:53 PM
#26540   This run will be different...actual revenue coming into Type0neg 08/20/17 01:55:44 PM
#26539   When? TheBrainTrust 08/20/17 01:25:08 PM
#26538   Depends if they don't continue to dilute TheBrainTrust 08/20/17 01:24:02 PM
#26537   Zip Code Changing Stock Run realtalk1337 08/20/17 01:21:12 PM
#26536   I dont know about this Friday but eventually knowmystuff 08/20/17 01:20:52 PM
#26535   $2 by Friday to the mooooon Cryptocol 08/20/17 01:14:11 PM
#26534   VDRM huge buys friday, kept bouncing off 017, yankees18 08/20/17 01:06:29 PM
#26533   Get ready for excitement on Monday. It will run Camelot 08/20/17 12:43:24 PM
#26532   VDRM-projects 1-mil projected-sales-Sept/Oct possible-jump-to $2.00? CyberJ 08/20/17 12:22:35 PM
#26531   Could-VDRM w/monthly-revs, jump-to-$2.00 on 1-mil monthly-projection? CyberJ 08/20/17 12:18:16 PM
#26530   $OWCP-w/no-revs, jumped-to-$3.23 on-projected monthly-revs-of $2-mil CyberJ 08/20/17 12:17:56 PM
#26529   OWCP$-and-VDRM enjoy-same low-share structure-meaning-both fast-gainers CyberJ 08/20/17 12:17:23 PM
#26528   Excellent color for sure. Volume was great and retired early 08/20/17 11:57:40 AM
#26527   Its not them. Different CEO hispeedsoul 08/20/17 11:26:53 AM
#26526   #18 on breakout board knowmystuff 08/20/17 11:23:33 AM
#26525   Hit many scanners over the weekend. knowmystuff 08/20/17 11:23:10 AM
#26524   Lots of new eyes here knowmystuff 08/20/17 11:22:45 AM
#26523   Board marks keep climbing. Was at 470 at knowmystuff 08/20/17 11:22:10 AM
#26522   I'm expecting another 100% day Monday and then knowmystuff 08/20/17 11:18:45 AM
#26521   GO knowmystuff 08/20/17 11:14:06 AM
#26520   V knowmystuff 08/20/17 11:13:49 AM
#26519   D knowmystuff 08/20/17 11:13:38 AM
#26518   R knowmystuff 08/20/17 11:13:27 AM
#26517   M knowmystuff 08/20/17 11:13:08 AM
#26516   !!!!!! knowmystuff 08/20/17 11:12:55 AM
#26515   Guys know what you own! This is going knowmystuff 08/20/17 11:11:14 AM
#26514   When the 10Q's start showing $1-2MM revenues. zombywolf 08/20/17 11:09:05 AM
#26513   i CAN ANSWER THAT :), IF SALES GO mgazel 08/20/17 11:06:18 AM
#26512   And that's just the japan revenue alone! knowmystuff 08/20/17 11:05:22 AM
#26511   Selling for 40% here is like selling amazon knowmystuff 08/20/17 11:03:35 AM
#26510   .47 by when in your opinion? This seems realistic Cryptocol 08/20/17 11:01:49 AM
#26509   I calculate .47 per share on the Japan zombywolf 08/20/17 11:00:17 AM
#26508   40% + i AM OUT :) , i mgazel 08/20/17 10:59:49 AM
PostSubject